Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Dr reddy laboratories | Mind Blowing Facts

QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it

India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. Takeda will retain rights for public market distribution as a future objective. QDENGA is a two-dose vaccine designed to protect against…

The Economic Times

Trump's Tariffs Are Targeting Indian Drugmakers. Americans Could Soon Pay More for Generic Medicines, CEO Warns

Erez Israeli, CEO of Dr. Reddy's Laboratories, said that President Donald Trump's proposed tariffs on imported generic medicines would inevitably translate into higher prices for patients.

International Business Times

200% Trump tariff shock? India’s cheap pills may still beat US rivals

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage may help many drugs remain competitive in the US market, according to the Global Trade Research Initiative (GTRI).

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Parag Parikh Flexi Cap increased stake in ITC, TCS, HCL Technologies, and 14 other stocks in June

Parag Parikh Flexi Cap Fund increased its holdings in ITC, TCS, HCL Technologies and 14 other stocks in June, while trimming exposure to Dr Reddy’s Laboratories and Maruti Suzuki India. The fund also added Petronet LNG as a new portfolio entrant and made no complete exits during the month.

The Economic Times

Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter. Narasimham said the company’s und

MarketBeat

Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh in

Dr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared with Rs 1,587 crore a year ago. Following the weak earnings performance, several brokerages cut their target prices on the stock.

The Economic Times

World Economic Forum recognition for Dr. Reddy’s plant

Facility in Bachupally, Hyderabad, now part of Global Lighthouse Network

The Hindu

Read news from The Economist, FT, and more,
with one subscription

Flow Chemistry Tech Hub opened in Hyderabad

Facility will be key to pharma R&D, adoption of continuous synthesis for making APIs

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Tata Consultancy Services

Parag Parikh Flexi Cap Fund

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.